CDCarina Joy Donegan

Carina Joy Donegan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carina Joy Donegan has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial

    by Dimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, Anna Forsyth, Soo Hee Jeong, William Evans, Malak Alshakhouri, Robin J. Murphy, Lisa Reynolds, Nicholas Hoeh, et al.


  • Open Access

    What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial

    by Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael L. Sumner, Anna Forsyth, Will Evans, Nicholas R. Hoeh, Frederick Sundram, David Menkes, Suresh Muthukumaraswamy, Lisa Reynolds

    Background: Depressive disorders affect approximately 280 million globally, with many finding treatments ineffective or limited by side effects. Growing evidence suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing shows promise for major depressive disorder (MDD). However, research on LSD microdosing in clinical populations remains limited. Objectives: This study aimed to understand the experiences of individuals participating in an open-label trial of LSD microdosing for MDD. Design: Open-label pilot trial in target population (MDD; phase IIa). Methods: Seventeen participants with MDD completed an 8-week LSD microdosing regimen, dosing twice weekly. Following the intervention, participants underwent semi-structured interviews regarding their experiences. Data were analysed using thematic analysis. Results: Themes were grouped into five categories: enhanced self-determination, increased connectedness, improved cognitive processing, better emotional well-being, and negative effects. Conclusion: Reported effects appeared to reinforce one another; that is, self-determination led to feeling more connected, which enhanced cognitive processing and ultimately improved emotional well-being and reduced depressive symptoms. However, this effect was not universal; some individuals reported negative effects or no significant improvement from microdosing LSD. This variability may be due to individual differences in response, insufficient dosage, or the treatment’s lack of effectiveness for some individuals. The presence of side effects highlights the need for a careful titration protocol, while the lack of symptom improvement in some cases reinforces that microdosing is not a guaranteed solution, and expectations should remain realistic. The absence of a placebo control represents a key limitation as it precludes attribution of observed changes specifically to LSD. Trial registration: ANZCTR, ACTRN12623000486628. Registered on 12 May 2023 ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385758 ).


  • Open Access

    LSD microdosing in major depressive disorder: results from an open-label trial

    by Dimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, Anna Forsyth, William Evans, Malak Alshakhouri, Lisa Reynolds, Rhys Ponton, Todd Smith, Partha Roop, et al.


  • Open Access

    Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures

    by Carina Joy Donegan, Dimitri Daldegan-Bueno, Tehseen Noorani, Rachael Sumner, Anna Forsyth, William Evans, Todd Smith, Nicholas Hoeh, Frederick Sundram, David Menkes, et al.


  • Open Access

    An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)

    by Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, David Menkes, William Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, et al.

    Background: Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies. In light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients to self-treat depression with microdoses of psychedelic drugs such as lysergic acid diethylamide (LSD) and psilocybin [3]. Beyond anecdotal reports from those who self-medicate in this way, few clinical trials have evaluated this practice. In our recently published phase 1 study in healthy volunteers [4], we determined that LSD microdosing was relatively safe and well tolerated in that cohort. Furthermore, the data demonstrated that conducting such microdosing trials is broadly feasible, with excellent adherence and compliance to the regimen observed. In this open-label pilot trial of patients with major depressive disorder (LSDDEP1), we will test the tolerability and feasibility of an 8-week regimen of LSD microdosing in this patient group prior to a larger subsequent randomised controlled trial (LSDDEP2). Methods: Twenty patients meeting the DSM-5 criteria for major depressive disorder will receive an 8-week LSD microdosing treatment regimen. The treatment protocol will use a sublingual formulation of LSD (MB-22001) delivered twice per week under a titration schedule using a dose of 5–15 µg. Tolerability will be assessed by quantifying the percentage of participants who withdraw from the trial due to adverse events attributable to the treatment regimen, while feasibility will be assessed by quantifying the percentage of attended clinic visits once enrolled. To determine whether there is any antidepressant response to the LSD microdosing regimen, MADRS scores will be assessed at baseline and 2, 4, 6, and 8 weeks after the commencement of the regimen. Discussion: The results of LSDDEP1 will provide valuable information regarding the tolerability and feasibility of a proposed LSD microdosing regimen in patients with MDD. Such information is critically important to optimise trial design prior to commencing a subsequent and more resource-intensive randomised controlled trial. Trial registration: ANZCTR, ACTRN12623000486628. Registered on 12 May 2023.